Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln

Sanofi (SASY) shares rose 1.4% to €73.65 after announcing an $8B collaboration with Regeneron to co-develop and co-commercialize four new antibodies. The deal includes a $1B upfront payment and up to $7B in milestone payments. Analysts have a Buy rating and a 12-month price target of €94.06, suggesting significant upside from current levels.

Sanofi will pay Regeneron $1B upfront and up to $7B in milestones for four new antibodies under their Dupixent partnership. Sanofi shares rose 2% on the news. The deal aims to strengthen Sanofi's pipeline before Dupixent's patent expiry. Regeneron will lead R&D, while Sanofi handles global sales. Profits and costs will be split equally, with existing Dupixent terms unchanged.

Sanofi and Regeneron expanded their collaboration with an $80B deal, including a $10B upfront payment. They will develop four new antibody therapies for inflammatory diseases. Regeneron will handle development, while Sanofi manages global sales. Regeneron's stock is considered 16.4% undervalued with a GF Score of 88/100, indicating strong financial health and growth potential.

Regeneron's experimental weight-loss drug, combined with Novo Nordisk's semaglutide, reduced muscle mass loss by 50% in a study. The trial involved patients using both drugs.

Sanofi and Regeneron Pharmaceuticals agreed to expand their alliance to develop and commercialize new immunology drugs. Regeneron will receive $1 billion upfront and up to $7 billion based on milestones. The companies will share costs and profits. They also settled prior litigation. The deal includes four Regeneron drug candidates and an option for Sanofi's lunsekimig.

Sanofi and Regeneron expanded their antibody collaboration, adding four new long-acting antibodies. Regeneron will receive $1bn upfront and up to $7bn in milestones. They will share development costs and profits equally. Sanofi will lead commercialization, while Regeneron leads R&D. The companies resolved prior disputes. Sanofi's net sales are primarily from pharmaceutical products, with significant U.S. market presence.